Potential antitumor effect of organochalcogenyl-benzoates in glioma cells
DOI:
https://doi.org/10.5902/2179460X74392Keywords:
Cancer, Glioblastoma, Selenium, Organic compoundsAbstract
In the domain of brain malignancies, glioma, in particular the World Health Organization (WHO) Grade IV Glioblastoma, persists as having one of the worst prognoses in modern medicine. Despite the protocol leading to the convention of surgery with chemo-radiotherapy as the mainstay of treatment, mean survival rarely exceeds 18 months. In this work, we tested the antiglioma potential of three organochalcogenyl-benzoates containing an organoselenium group in their structure, obtained by chemical synthesis: 3-(phenylselanyl)prop-2-yn-1-yl nicotinate, 3-(phenylselanyl)benzoate)prop-2-yn-1-yl, and 3-((4-fluorophenyl)selanyl)prop-2-yn-1-yl benzoate. The tests were performed on a C6 rat glioblastoma cell line, which was treated with the compounds for different times (24, 48, and 72 hours) and concentrations (10-100 µM). After the treatments, MTT assays and cell counts were performed. All compounds showed cytotoxic effects, decreasing cell viability and the number of cells. For compound 3-((4-fluorophenyl)selanyl)prop-2-in-1-yl benzoate—which showed the most pronounced cytotoxic effects— analyses of cumulative population doubling, clonogenic ability, induction potential of senescence, and lipid peroxidation were performed. The compound was only able to induce a significant increase in lipid peroxidation, with no effect over the other parameters studied. The results presented here are unprecedented and promising, introducing new compounds with antitumor potential for glioma therapy.
Downloads
References
Agani, C. A. J. O. (2018). Estabelecimento de linhagem de glioblastoma humano resistente ao quimioterápico temozolomide. [Trabalho de conclusão de curso, Universidade Federal do Rio Grande do Sul]. http://hdl.handle.net/10183/206854.
Bartusik-Aebisher, D., Chrzanowski, G., Bober, Z., & Aebisher, D. (2021). An analytical study of Trastuzumab-dendrimer-fluorine drug delivery system in breast cancer therapy in vitro. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 133, 11105, 2021. https://doi.org/10.1016/j.biopha.2020.111053. DOI: https://doi.org/10.1016/j.biopha.2020.111053
Calcinotto, A., Kohli, J., Zagato, E., Pellegrini, L., Demaria, M., & Alimonti, A. (2019). Cellular senescence: aging, cancer, and injury. Physiological reviews, 99(2), 1047-1078, 2019. http://doi.org/10.1152/physrev.00020.2018. DOI: https://doi.org/10.1152/physrev.00020.2018
Davis, M. E. (2016). Glioblastoma: overview of disease and treatment. Clinical journal of oncology nursing, 20(5 Suppl), S2-S8. http://doi.org/10.1188/16.CJON.S1.2-8. DOI: https://doi.org/10.1188/16.CJON.S1.2-8
Diasio, R. B., & Harris, B. E. (1989). Clinical pharmacology of 5-fluorouracil. Clinical Pharmacokinetics, 16(4), 215–237. http://doi.org/10.2165/00003088-198916040-00002. DOI: https://doi.org/10.2165/00003088-198916040-00002
Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., … & Campisi, J. (1995). A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proceedings of the National Academy of Sciences of the United States of America, 92(20), 9363–9367. http://doi.org/10.1073/pnas.92.20.9363. DOI: https://doi.org/10.1073/pnas.92.20.9363
Ferreira, Á. L. G. (2013). Novos Processos de Fluoração em Química Farmacêutica Industrial. [Dissertação de Mestrado em Química Farmacêutica Industrial, Universidade de Coimbra]. https://hdl.handle.net/10316/37508
Franken, N. A. P., Rodermond, H. M., Stap, J., Haveman, J., & Van Bree, C. (2006). Clonogenic assay of cells in vitro. Nature protocols, 1(5), 2315–2319. http://doi.org/10.1038/nprot.2006.339. DOI: https://doi.org/10.1038/nprot.2006.339
Giles, N. M., Giles, G. I., Gutowski, N. J., & Jacob, C. (2003). Redox catalysts as sensitizers towards oxidative stress. FEBS letters, 535(1-3), 179-182. http://doi.org/10.1016/S0014-5793(02)03890-5. DOI: https://doi.org/10.1016/S0014-5793(02)03890-5
Giles, N. M., Giles, G. I., Holley, J. E., Gutowski, N. J., & Jacob, C. (2003). Targeting oxidative stress-related diseases: organochalcogen catalysts as redox sensitizers. Biochemical pharmacolpgy, 66(10), 2021–2028. http://doi.org/10.1016/S0006-2952(03)00544-6. DOI: https://doi.org/10.1016/S0006-2952(03)00544-6
Gritzenco, F. (2020). Síntese de benzoatos 3-(organocalcogenil)prop-2-in-1-ílicos catalisada por cobre: aplicação sintética e potencial farmacológico. [Dissertação de mestrado (Programa de Pós-graduação em Ambiente e Tecnologias Sustentáveis, Universidade Federal da Fronteira Sul]. https://rd.uffs.edu.br/handle/prefix/3972.
Gritzenco, F., Kazmierczak, J. C., Anjos, T., Sperança, A., Peixoto, M. L. B., Ledebuhr, K. N. B., Bruning, C.A., ... & Godoi, B. (2021). Base-Free synthesis and synthetic applications of novel 3-(Organochalcogenyl)prop-2-yn-1-yl esters: promising anticancer agents. Synthesis, 53(15), 2676-2688. http://doi.org/10.1055/a-1477-6470. DOI: https://doi.org/10.1055/a-1477-6470
Hayflick, L. The limited in vitro lifetime of human diploid cell strains. (1965). Experimental Cell Research, 37, 614-636. http://doi.org/10.1016/0014-4827(65)90211-9. DOI: https://doi.org/10.1016/0014-4827(65)90211-9
Hong, J., Zeng, X. A., Brennan, C. S., Brennan, M., & Han, Z. (2016). Recent advances in techniques for starch esters and the applications: a review. Foods, 5(3), 50. http://doi.org/ 10.3390/foods5030050. DOI: https://doi.org/10.3390/foods5030050
INCA - Instituto Nacional do Câncer. (2019). Estimativa 2020: incidência de câncer no Brasil / Instituto Nacional de Câncer José Alencar Gomes da Silva – Rio de Janeiro: INCA Available at: https://www.inca.gov.br/sites/ufu.sti.inca.local/files/media/document/estimativa-2020-incidencia-de-cancer-no-brasil.pdf. Access in: 03/07/2022.
Kaushik, C. P., Pahwa, A., Kumar, D., Kumar, A., Singh, D., Kumar, K., & Luxmi, R. (2018). Synthesis and antimicrobial evaluation of (1-(2-(Benzyloxy)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)methyl benzoate analogues. Journal of heterocyclic chemistry, 55(7), 1720-1728. http://doi.org/10.1002/jhet.3209. DOI: https://doi.org/10.1002/jhet.3209
Klein, D. (2016) Química Orgânica. Compostos aromáticos. 2. ed. Rio de Janeiro: Ltc, 18,154-195.
Kubanek, J., Prusak, A. C., Snell, T. W., Giese, R. A., Hardcastle, K. I., Fairchild, C. R. Aalbersberg, W., … & Hay, M. (2005). Antineoplastic Diterpene−Benzoate Macrolides from the Fijian Red Alga Callophycus serratus. Organic letters, 7(23), 5261-5264. http://doi.org/10.1021/ol052121f. DOI: https://doi.org/10.1021/ol052121f
Li, T., Smet, M., Dehaen, W., & Xu, H. (2015). Selenium − Platinum coordination dendrimers with controlled anti-cancer activity. ACS applied materials & interfaces, 8(6), 3609-3614. http://doi.org/10.1021/acsami.5b07877. DOI: https://doi.org/10.1021/acsami.5b07877
Longley, D. B., Harkin, P., & Johnston, P. G. (2003). 5-Fluorouracil: mechanisms of action and clinical strategies. Nature reviews cancer, 3, 330-338. http://doi.org/10.1038/nrc1074. DOI: https://doi.org/10.1038/nrc1074
Magalhães, H. I. C. (2018). Efeitos do Flúor na Saúde Humana. [Dissertação de Mestrado em Ciências Farmacêuticas. Universidade Fernando Pessoa]. http://hdl.handle.net/10284/7327.
Martínez, M. A., Rodríguez, J. L., Lopez-Torres, B., Martínez, M., Martínez-Larrañaga, M. R., Maximiliano, J. H., … & Ares, I. (2020). Use of human neuroblastoma SH-SY5Y cells to evaluate glyphosate-induced effects on oxidative stress, neuronal development and cell death signaling pathways. Environment international, 135, 105414. http://doi.org/10.1016/j.envint.2019.105414. DOI: https://doi.org/10.1016/j.envint.2019.105414
Mosmann, T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Journal of immunological methods, 65(1-2), 55-63. http://doi.org/10.1016/0022-1759(83)90303-4. DOI: https://doi.org/10.1016/0022-1759(83)90303-4
Ostrom, Q. T., Bauchet, L., Davis, F. G., Deltour, I., Fischer, J. L., Langer, C. E., Pekmezci, M., … & Barnholtz-Sloan, J. S. (2014). The epidemiology of glioma in adults: A “state of the science” review. Neuro-oncology, 16(7), 896–913. http://doi.org/10.1093/neuonc/nou087. DOI: https://doi.org/10.1093/neuonc/nou087
Ou, H-L., Hoffmann, R., Gonzalez-Lopez, C., Doherty, G. J., Korkola, J. E., & Munoz-Espin, D. Cellular senescence in cancer: from mechanisms to detection. (2021). Molecular oncology, 15(10), 2634–2671. http://doi.org/10.1002/1878-0261.12807. DOI: https://doi.org/10.1002/1878-0261.12807
Phillips, H. S., Kharbanda, S., Chen, R., Forrest, W. F., Soriano, R. H., Wu, T. D., Misra, A., …& Aldape, K. (2006). Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell, 9, 157–173. http://doi.org/10.1016/j.ccr.2006.02.019. DOI: https://doi.org/10.1016/j.ccr.2006.02.019
Rang, H. P., Ritter, J. M., Flower, R. J., & Henderson, G. (2016). Pharmacology. 8. ed. Rio de Janeiro: Elsevier.
Rosa, S. G., Brüning, C. A., Pesarico, A. P., Souza, A. C. G., & Nogueira, C. W. (2018). Anti-inflammatory and antinociceptive effects of 2,2`-
dipyridyl diselenide through reduction of inducible nitric oxide synthase, nuclear factor-kappa b and c-jun n-terminal kinase
phosphorylation levels in the mouse spinal cord. Trace Elements, 48, 38-45. http://doi.org/10.1016/j.jtemb.2018.02.021. DOI: https://doi.org/10.1016/j.jtemb.2018.02.021
Silva, A. O., Dalsin, E., Onzi, G. R., Filippi-Chiela, E. C., & Lenz, G. (2016). The regrowth kinetic of the surviving population is independent
of acute and chronic responses to temozolomide in glioblastoma cell lines. Experimental cell research, 348(2), 177–183. http://doi.org/10.1016/j.yexcr.2016.09.014. DOI: https://doi.org/10.1016/j.yexcr.2016.09.014
Stupp, R., Taillibert, S., Kanner, A. A., Kesari, S., Steinberg, D. M., Toms, S. A., Taylor, L. P., … & Ram, Z. (2015). Maintenance therapy with
tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA, 314(23), 2535–2543.
http://doi.org/10.1001/jama.2015.16669. DOI: https://doi.org/10.1001/jama.2015.16669
Thomas, C. J. (2006). Fluorinated natural products with clinical significance. Current topics in medicinal chemistry, 6(14), 1529-1543. http://doi.org/10.2174/156802606777951109. DOI: https://doi.org/10.2174/156802606777951109
Weller, M., Van Den Bent, M., Hopkins, K., Tonn, J. C., Stupp, R., Falini, A., Cohen-Jonathan-Moyal, E, … & Wick, W. (2014). EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. The Lancet. Oncology, 15(9), e395-e403. http://doi.org/10.1016/S1470-2045(14)70011-7. DOI: https://doi.org/10.1016/S1470-2045(14)70011-7
Wen, P. Y., Kesari, S. (2008). Malignant gliomas in adults. The New England journal of medicine, 359(5), 492-507. http://doi.org/10.1056/NEJMra0708126. DOI: https://doi.org/10.1056/NEJMra0708126
WORLD HEALTH ORGANIZATION – WHO (1997). Model Prescribing Information: drugs used in skin diseases. Geneva.
WORLD HEALTH ORGANIZATION – WHO (2018). Global Health Estimates 2016: Deaths by Cause, Age, Sex, by Country and by Region.
Geneva.
Yakubov, E., Buchfelder, M., Eyüpoglu, I. Y., & Savaskan, N. E. (2014). Selenium action in neuro-oncology. Biological Trace Element Research, 161, 246–254. http://doi.org/10.1007/s12011-014-0111-8. DOI: https://doi.org/10.1007/s12011-014-0111-8
Yakubov, E., Eibl, T., Hammer, A., Holtmannspötter, M., Savaskan, N., & Steiner, H-H. (2021). Therapeutic potential of selenium in glioblastoma. Frontiers in Neuroscience, 15, 1-12. http://doi.org/10.3389/fnins.2021.666679. DOI: https://doi.org/10.3389/fnins.2021.666679
Yamanaka, R., Saya, H. (2009). Molecularly targeted therapies for glioma. Annals of Neurology, 66, 717-729. http://doi.org/10.1002/ana.21793. DOI: https://doi.org/10.1002/ana.21793
Zamin, L. L., Filippi-Chiela, E. C., Dillenburg-Pilla, P., Horn, F., Salbego, C., & Lenz, G. (2009). Resveratrol and quercetin cooperate to induce senescence-like growth arrest in C6 rat glioma cells. Cancer Science, 100(9), 1655-1662. http://doi.org/10.1111/j.1349-7006.2009.01215.x DOI: https://doi.org/10.1111/j.1349-7006.2009.01215.x
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Ciência e Natura
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
To access the DECLARATION AND TRANSFER OF COPYRIGHT AUTHOR’S DECLARATION AND COPYRIGHT LICENSE click here.
Ethical Guidelines for Journal Publication
The Ciência e Natura journal is committed to ensuring ethics in publication and quality of articles.
Conformance to standards of ethical behavior is therefore expected of all parties involved: Authors, Editors, Reviewers, and the Publisher.
In particular,
Authors: Authors should present an objective discussion of the significance of research work as well as sufficient detail and references to permit others to replicate the experiments. Fraudulent or knowingly inaccurate statements constitute unethical behavior and are unacceptable. Review Articles should also be objective, comprehensive, and accurate accounts of the state of the art. The Authors should ensure that their work is entirely original works, and if the work and/or words of others have been used, this has been appropriately acknowledged. Plagiarism in all its forms constitutes unethical publishing behavior and is unacceptable. Submitting the same manuscript to more than one journal concurrently constitutes unethical publishing behavior and is unacceptable. Authors should not submit articles describing essentially the same research to more than one journal. The corresponding Author should ensure that there is a full consensus of all Co-authors in approving the final version of the paper and its submission for publication.
Editors: Editors should evaluate manuscripts exclusively on the basis of their academic merit. An Editor must not use unpublished information in the editor's own research without the express written consent of the Author. Editors should take reasonable responsive measures when ethical complaints have been presented concerning a submitted manuscript or published paper.
Reviewers: Any manuscripts received for review must be treated as confidential documents. Privileged information or ideas obtained through peer review must be kept confidential and not used for personal advantage. Reviewers should be conducted objectively, and observations should be formulated clearly with supporting arguments, so that Authors can use them for improving the paper. Any selected Reviewer who feels unqualified to review the research reported in a manuscript or knows that its prompt review will be impossible should notify the Editor and excuse himself from the review process. Reviewers should not consider manuscripts in which they have conflicts of interest resulting from competitive, collaborative, or other relationships or connections with any of the authors, companies, or institutions connected to the papers.
